Literature DB >> 6834275

Effects of nimodipine on cerebral blood flow.

C W Haws, J K Gourley, D D Heistad.   

Abstract

The purposes of this study were to compare the effects of the calcium entry blocker nimodipine (Bay e 9736) on blood flow with brain and other organs and to examine effects on regional cerebral blood flow. Cerebral blood flow was measured by the microsphere method. Determinations were made during intracarotid and i.v. nimodipine infusions in anesthetized and unanesthetized rabbits. In unanesthetized rabbits, i.v. infusion of 0.1 micrograms/kg x min nimodipine produced a 2-fold increase in cerebral blood flow and a 1.5-fold increase in myocardial flow without an increase in blood flow to other organs and with a small decrease in arterial pressure. A dose of 1.0 micrograms/kg x min produced further increases in flow to brain, myocardium and muscle despite reducing arterial pressure. Blood flow increased significantly in both cerebral gray and white matter and increased similarly in cerebrum, cerebellum and brainstem. In anesthetized rabbits, intracarotid infusion of nimodipine produced dose-dependent increases in cerebral blood flow; i.v. nimodipine produced an increase in cerebral blood flow with no change in cerebral O2 consumption. Thus, at low doses that have little effect on aortic pressure, nimodipine causes a selective increase in cerebral and myocardial blood flow. Nimodipine increases blood flow in all regions of the brain. The increase in blood flow is the result of a direct vasodilator effect and is not secondary to increased cerebral metabolism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834275

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  The role of calcium antagonists in the treatment of cerebrovascular disease.

Authors:  J J Murphy
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

2.  Myogenic contraction by modulation of voltage-dependent calcium currents in isolated rat cerebral arteries.

Authors:  J G McCarron; C A Crichton; P D Langton; A MacKenzie; G L Smith
Journal:  J Physiol       Date:  1997-01-15       Impact factor: 5.182

3.  Local cerebral glucose utilization and local cerebral blood flow in conscious rats after administration of flunarizine.

Authors:  T Beck; J Krieglstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

4.  The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat.

Authors:  J Hauerberg; G Rasmussen; M Juhler; F Gjerris
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  A bout analysis reveals age-related methylmercury neurotoxicity and nimodipine neuroprotection.

Authors:  Andrew Nathanael Shen; Craig Cummings; Derek Pope; Daniel Hoffman; M Christopher Newland
Journal:  Behav Brain Res       Date:  2016-05-16       Impact factor: 3.332

Review 6.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Experimental intracerebral haemorrhage: the effect of nimodipine pretreatment.

Authors:  E J Sinar; A D Mendelow; D I Graham; G M Teasdale
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

8.  The acute effect of nimodipine on cerebral blood flow, its CO2 reactivity, and cerebral oxygen metabolism in human volunteers.

Authors:  J F Schmidt; G Waldemar; O B Paulson
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

9.  Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine.

Authors:  André Gustavo Tempone; Noemi Nosomi Taniwaki; Juliana Quero Reimão
Journal:  Parasitol Res       Date:  2009-04-08       Impact factor: 2.289

10.  Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls.

Authors:  F M Gengo; S C Fagan; G Krol; H Bernhard
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.